FDA Greenlights BioMarin's Palynziq for Adolescent PKU Patients, Expanding Rare Disease Treatment Options

The U.S. Food and Drug Administration (FDA) on Friday cleared BioMarin Pharmaceutical Inc.'s Palynziq for use in adolescents aged 12 and older who are living with phenylketonuria (PKU), a rare and serious inherited metabolic disorder. The decision significantly broadens access to the only available enzyme substitution therapy for managing PKU beyond adult patients.

PKU prevents the body from properly breaking down the amino acid phenylalanine, leading to its dangerous accumulation in the blood. If untreated, it can cause severe and irreversible intellectual disability, neurological problems, and behavioral issues. Management has historically relied on a highly restrictive, lifelong low-protein diet, which is particularly challenging for adolescents.

"This approval addresses a critical unmet need for younger patients and their families," said a senior FDA official. "It provides an important therapeutic option alongside dietary management for a population where consistent dietary control can be difficult."

The regulatory nod is based on robust data from the Phase 3 PEGASUS study. The trial demonstrated that Palynziq (pegvaliase-pqpz) injection led to statistically significant and clinically meaningful reductions in blood phenylalanine levels compared to diet alone over 72 weeks. BioMarin has also submitted an application to the European Medicines Agency, seeking a similar label expansion in the EU.

For BioMarin, a leader in rare disease therapeutics, this approval strengthens its flagship PKU portfolio, which also includes Kuvan. The company faces competitive pressure but solidifies its position in the niche market. Analysts view the label expansion as a positive, albeit expected, catalyst for long-term revenue stability.

Market Context & Analyst Outlook: Despite the regulatory win, BioMarin's stock (NASDAQ: BMRN) has faced headwinds, trading down nearly 19% over the past year amid a broader biotech slump. Technical indicators present a mixed picture, with the stock below key moving averages but holding a neutral Relative Strength Index. The consensus analyst rating remains a "Buy," with an average price target of $88.80, suggesting significant upside potential from current levels.

Voices from the Community

Dr. Anya Sharma, Pediatric Metabolic Geneticist, Boston Children's Hospital: "This is a practice-changing decision. We've seen the life-altering impact of this therapy in adults. Extending it to adolescents allows us to intervene earlier, potentially improving long-term cognitive and quality-of-life outcomes. The data on safety and efficacy in this age group is compelling."

Michael Torres, Father of a 14-year-old with PKU: "It's a ray of hope. The daily struggle with the diet is immense for a teenager who just wants to be like their friends. This isn't a cure, but it's a powerful tool that could give my son more freedom and less anxiety around every single bite of food. The approval process felt long, but we're grateful it's here."

David K. Lynch, Healthcare Policy Analyst: "While scientifically sound, we must scrutinize the cost-access equation. BioMarin's therapies are among the most expensive in the world. Will insurers cover this for adolescents without brutal prior authorization battles? This approval could exacerbate healthcare inequities if access isn't ensured for all families, not just the well-insured."

Lisa Chen, Portfolio Manager at a Life Sciences Fund: "This was a key regulatory milestone priced into the model. The real focus now is on execution—commercial penetration in the adolescent segment and the ongoing launch in younger pediatric patients. The stock's weakness reflects macro sentiments more than product-specific concerns. The underlying PKU franchise remains a durable asset."